Brief: Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc
June 2 (Reuters) - Zai Lab Ltd 9688.HK: ZAI LAB PRESENTS POSITIVE PHASE 1 DATA FOR ZL-1310, A DLL3-TARGETED ADC, DEMONSTRATING ROBUST ANTI-TUMOR ACTIVITY AND SAFETY IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER AT 2025 ASCO ANNUAL MEETING Source text: ID:nBwzHvjLa Further company coverage: 9688.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows